Metallo-Drugs: Development and Action of Anticancer Agents
Ed. by Sigel, Astrid / Sigel, Helmut / Freisinger, Eva / Sigel, Roland K.O.
With contrib. by Riddell, Imogen / Lippard, Stephen J. / Brabec, Victor / Kasparkova, Jana / Menon, Vijay / Farrell, Nicholas P. / Venkatesh, V. / Sadler, Peter J. / Gorle, Anil K. / Peterson, Erica J. / Berners-Price, Susan / Alessio, Enzo / Messori, Luigi / Babak, Maria V. / Ang, Wee Han / Casini, Angela / Sun, Raymond Wai-Yin / Ott, Ingo / Tshuva, Edit / Miller, Maya / Crans, Debbie / Yan, Lining / Haase, Allison / Yang, Xiaogai / Chitambar, Christopher / Cardo, Lucia / Hannon, Michael John / Vilar, Ramon / Sullivan, Matthew P. / Holtkamp, Hannah U. / Hartinger, Christian G. / Schatzschneider, Ulrich / Thévenod, Frank / Denoyer, Delphine / Clatworthy, Sharnel A. S. / Cater, Michael / Ziliotto, Silvia / Ogle, Olivia / Taylor, Kathryn M.
Series:Metal Ions in Life Sciences 18
- Creating a unique snapshot of current understanding on metallo-drugs.
- Providing a view on how knowledge is guiding new metallo-drug design.
Aims and Scope
Volume 18, entitled Metallo-Drugs: Development and Action of Anticancer Agents of the series Metal Ions in Life Sciences centers on biological, medicinal inorganic chemistry. The serendipitous discovery of the antitumor activity of cis-diamminodichloroplatinum(II) (cisplatin) by Barnett Rosenberg in the 1960s is a landmark in metallodrug-based chemotherapy. The success of cisplatin in the clinic, followed by oxaliplatin and carboplatin, along with their drawbacks relating mainly to resistance development and severe toxicity, initiated research on polynuclear platinum complexes and on Pt(IV) complexes as prodrugs. Furthermore, the indicated shortcomings led to the exploration of other transition and main group metal ions, among them Ru(II/III), Au(I/III), Ti(IV), V(IV/V), and Ga(III) including also the essential metal ions Fe(II/III), Cu(I/II), and Zn(II). Ionic as well as covalent and non-covalent interactions between structurally very different complexes and biomolecules like nucleic acids, proteins, and carbohydrates are studied and discussed with regard to their possible anticancer actions. Hence, MILS-18 summarizes the research at the forefront of medicinal inorganic chemistry, including studies on the next-generation, tailor-made anticancer drugs. All this and more is treated in an authoritative and timely manner in the 17 stimulating chapters of this book, written by 39 internationally recognized experts from 10 nations (from the US via Europe to China and Australia). The impact of this vibrant research area is manifested by more than 2700 references, nearly 150 illustrations (more than half in color) and several comprehensive tables. Metallo-Drugs: Development and Action of Anticancer Agents is an essential resource for scientists working in the wide range from enzymology, material sciences, analytical, organic, and inorganic biochemistry all the way through to medicine including the clinic ... not forgetting that it also provides excellent information for teaching.
- xlii, 546 pages
- Type of Publication:
MARC recordMARC record for eBook
"Volume 18 of MILS is an excellent update on a vibrant field within Bioinorganic Chemistry, the role of metal species in the treatment of cancer. It reflects both the successes of metallo-drugs in the clinic, their failures and shortcomings, and at the same time also promises and hopes for improved drugs in the future. The book is, as stated by the editors, indeed an “essential resource for scientists in this field” and a valuable source for teachers of relevant Bioinorganic Chemistry courses."
Bernhard Lippert in: Inorganica Chimica Acta 479 (2018) 247–248
"This latest volume of the series on Metal Ions in Life Sciences will be a valuable addition to libraries of researchers and institutions active in cancer research, but also a helpful source for advanced teaching of the subject." [H. Schmidbaur, Z. Naturforsch. B (2018)]